Get the Stockscreener App
26.74
0.34%
0.09
After Hours:
26.72
-0.02
-0.07%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc Stock (PFE) Latest News
Bernstein cuts Pfizer stock target to $30, keeps Market Perform By Investing.com - Investing.com South Africa
Bernstein cuts Pfizer stock target to $30, keeps Market Perform - Investing.com India
Haleon announces board change as Pfizer reduces stake - Investing.com
Haleon PLC Announces Board Change Following Pfizer Shareholding Reduction - TipRanks
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - Nasdaq
Former CDER director joins Pfizer as new chief medical officer - The Pharma Letter
The Zacks Analyst Blog Highlights Alibaba, Pfizer, MercadoLibre and SIFCO - Nasdaq
Ex-CDER chief Cavazzoni rejoins Pfizer as CMO - pharmaphorum
Former FDA director Patrizia Cavazzoni rejoins Pfizer - Medical Dialogues
Antibody Drug Conjugates Market Growth, Trends & Forecast - openPR
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - The Manila Times
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment? - StockTitan
Top Research Reports for Alibaba, Pfizer & MercadoLibre - Nasdaq
Pfizer Says Patrizia Cavazzoni Will Rejoin Co As Chief Medical Officer, Executive Vice President - Marketscreener.com
Pfizer hires ex-FDA drug chief as top doctor - The Hill
Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency - Barron's
Pfizer names former FDA director as chief medical officer - Reuters
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - GlobeNewswire Inc.
Pfizer sets sights on Summit’s bispecific in combo with its ADCs - Yahoo Finance
Pfizer And Summit Move Fast To Combine Ivonescimab With ADCs - News & Insights
Summit partners with Pfizer to study bispecific, ADC combinations - BioPharma Dive
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer - KFGO
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer - BioPharma Dive
Pfizer Names Former FDA Drug Chief as Top Doctor - Bloomberg
Pfizer shelves Beqvez, a Spark Therapeutics developed product - The Business Journals
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer -February 24, 2025 at 11:13 am EST - Marketscreener.com
Pfizer: What The Summit Therapeutics Deal Brings (NYSE:PFE) - Seeking Alpha
Pfizer : Announces New Chief Medical Officer -February 24, 2025 at 10:35 am EST - Marketscreener.com
Pfizer’s Beqvez decision lays bare gene therapy challenges - The Pharma Letter
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire
Pfizer: collaboration agreement with Summit Therapeutics -February 24, 2025 at 09:56 am EST - Marketscreener.com
Peninsula drugmaker nails heart failure drug launch in battle with Big Pharma - San Francisco Business Times
Neuralgia Treatment Market Booming with Advanced Therapies | Growth & Future Forecast: GlaxoSmithKline PLC, - EIN News
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday -February 24, 2025 at 09:15 am EST - Marketscreener.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Summit Therapeutics shares rise on Pfizer trial collaboration - Investing.com
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) - StreetInsider.com
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos -February 24, 2025 at 07:00 am EST - Marketscreener.com
Pfizer drops Beqvez, leaving its gene therapy cupboard bare - pharmaphorum
Summit Therapeutics Collaborates With Pfizer To Evaluate Ivonescimab Trial -February 24, 2025 at 06:44 am EST - Marketscreener.com
Can This New Summit-Pfizer Cancer Drug Combo Transform Solid Tumor Treatment? - StockTitan
Volumes spurt at Pfizer Ltd counter - Business Standard
Pfizer shares zoom nearly 9% after marketing and supply agreement with Mylan Pharmaceuticals - The Economic Times
Pfizer shares rise by 7% after marketing and sale pact with Mylan for two neuro therapy brands - Moneycontrol
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval - MedCity News
Are Pharma Stocks the Hidden Gems of 2024? Unveiling Pfizer’s Potential - Jomfruland.net
Pfizer Inc. (PFE): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts - Yahoo Finance
Pfizer: No More GrowthStill A Worthy Dividend Buy (NYSE:PFE) - Seeking Alpha
Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market - News & Insights
Pharma giant's pullback from gene therapy puts spotlight on North Carolina operations - The Business Journals
Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez - CGTLive™
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes - Yahoo Finance
Pfizer shelves haemophilia gene therapy Beqvez amid low demand - Yahoo Finance
Pfizer: Investors Won't Stick Around Forever (NYSE:PFE) - Seeking Alpha
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair - BioPharma Dive
Pfizer stops selling hemophilia gene therapy, citing weak demand - BioPharma Dive
An awkward moment for Pfizer’s Bourla in Washington - STAT
Topical Drug Delivery Market Booming Innovations & Forecast 2032 with Johnson & Johnson, Pfizer Inc., GSK plc, - EIN News
Is Pfizer Inc. (PFE) the Best Non-Tech Stock to Buy Now for Long Term? - Insider Monkey
Capital Advisory Group Advisory Services LLC Makes New $292,000 Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
Bradley Foster & Sargent Inc. CT Purchases 139,215 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Health Rounds: Swabs as good as unpleasant speculum exam for detecting cancer-causing HPV - Marketscreener.com
Pfizer Inc. (NYSE:PFE) is WP Advisors LLC's 5th Largest Position - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Kentucky Retirement Systems Insurance Trust Fund - MarketBeat
Compass Capital Corp MA ADV Buys Shares of 49,457 Pfizer Inc. (NYSE:PFE) - MarketBeat
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):